About Us
We pioneered the first multi-omic clinical test for coronary heart disease (CHD),
integrating epigenetics, genetics, and artificial intelligence to deliver scalable,
precise, and personalized cardiovascular solutions that improve lives.
Our Story
Cardio Diagnostics was founded in 2017 by Dr. Meesha Dogan, our Chief Executive Officer, and Dr. Rob Philibert, our Chief Medical Officer. But the seeds of our innovation were planted long before then. 15 years before that, their pioneering work in epigenetics began, followed by the groundbreaking application of artificial intelligence. These early pursuits converged in the invention of our core technology, developed in collaboration with Dr. Tim Dogan, our Chief Technology Officer and the first official team member at Cardio Diagnostics.
From day one, our founders shared a bold vision: that precision cardiovascular medicine, powered by the combination of epigenetics and artificial intelligence, could transform how cardiovascular disease is detected, managed, and ultimately prevented.
Heart disease remains the leading cause of death worldwide. Yet too often, detection comes too late, and care is reactive rather than proactive. Our purpose is to close this gap with solutions that enable earlier detection, more precise management, and better long-term outcomes.
Our Vision
We envision a healthcare system that no longer waits for a heart attack to act. A world where:
Heart disease is no longer the number one killer
What Makes Us Different
Expert-Led Innovation
Our team includes pioneers in epigenetics and AI, world-class scientists, clinicians, and technologists with deep expertise in cardiovascular medicine, molecular biology, and artificial intelligence.
Next-Gen Technology
We integrate our patented and proprietary epigenetic, genetic and artificial intelligence technologies to decode molecular signals that traditional tests miss. This allows us to uncover disease processes earlier and more precisely than ever before.
Dynamic Biomarkers
We go beyond proxy biomarkers. Our technology interprets DNA methylation and genetic variations to identify dynamic biological changes, enabling earlier detection and precision intervention in cardiovascular care.
Scale and Accessibility
Our tests integrate seamlessly into existing clinical workflows, requiring minimal training and no additional equipment. This accessibility ensures that precision cardiovascular care can reach more patients than ever before.
Recognized for Excellence in Technology and Innovation
